Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co.

Merck & Co. faces headwinds despite being labeled an undervalued stock. Morgan Stanley recently lowered its price target to ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of ...

The rally came despite a broader market volatility during the period, largely due to global trade worries over the United States’ imposition of tariffs against its trading partners, with China ...

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...